Prof. William Camu
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
Koch J, Leha A, Bidner H, Cordts I, Dorst J, Günther R, Zeller D, Braun N, Metelmann M, Corcia P, Depla E, Weydt P, Meyer T, Grosskreutz J, Soriani M, Attarian S, Weishaupt J, Weyen U, Kuttler J, Zurek G, Rogers M, Feneberg E, Deschauer M, Neuwirth C, Wuu J, Ludolph A, Schmidt J, Remane Y, Camu W, Friede T, Benatar M, Weber M, Lingor P, ROCK-ALS Study group. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2024; 23:1133-1146.
Nov 1, 2024Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
Nov 1, 2024Lancet Neurol 2024; 23:1133-1146
Koch Jan Christoph, Leha Andreas, Bidner Helen, Cordts Isabell, Dorst Johannes, Günther René, Zeller Daniel, Braun Nathalie, Metelmann Moritz, Corcia Philippe, Depla Erik, Weydt Patrick, Meyer Thomas, Grosskreutz Julian, Soriani Marie-Hélène, Attarian Shahram, Weishaupt Jochen H, Weyen Ute, Kuttler Josua, Zurek Gabriela, Rogers Mary-Louise, Feneberg Emily, Deschauer Marcus, Neuwirth Christoph, Wuu Joanne, Ludolph Albert C., Schmidt Jens, Remane Yvonne, Camu William, Friede Tim, Benatar Michael, Weber Markus, Lingor Paul, ROCK-ALS Study group
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist M, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg L, Juntas-Morales R, Chio A, Andersen P, Pradat P, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal N, Meyer T, Hanna M, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph A, Neuwirth C, Nations S, Shefner J, Turner M, Wuu J, Bennett R, Dang H, Sundgreen C, ORARIALS-01 trial team. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol 2024; 23:687-699.
May 20, 2024Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
May 20, 2024Lancet Neurol 2024; 23:687-699
Benatar Michael, Hansen Thomas, Rom Dror, Geist Marie A, Blaettler Thomas, Camu William, Kuzma-Kozakiewicz Magdalena, van den Berg Leonard H, Juntas-Morales Raul, Chio Adriano, Andersen Peter Munch, Pradat Pierre-Francois, Lange Dale J, Van Damme Philip, Mora Gabriele, Grudniak Mariusz, Elliott Matthew, Petri Susanne, Olney Nicholas, Ladha Shafeeq S, Goyal Namita A, Meyer Thomas, Hanna Michael G, Quinn Colin, Genge Angela, Zinman Lorne, Jabari Duaa, Shoesmith Christen, Ludolph Albert C., Neuwirth Christoph, Nations Sharon, Shefner Jeremy M, Turner Martin R, Wuu Joanne, Bennett Richard, Dang Hoang, Sundgreen Claus, ORARIALS-01 trial team
Clinical trials in pediatric ALS: a TRICALS feasibility study.
Kliest T, van Eijk R, Al-Chalabi A, Albanese A, Andersen P, Amador M, BrÅthen G, Brunaud-Danel V, Brylev L, Camu W, de Carvalho M, Cereda C, Cetin H, Chaverri D, Chio A, Corcia P, Couratier P, De Marchi F, Desnuelle C, van Es M, Esteban J, Filosto M, GarcÍa Redondo A, Grosskreutz J, Hanemann C, Holmøy T, HØyer H, Ingre C, Koritnik B, Kuzma-Kozakiewicz M, Lambert T, Leigh P, Lunetta C, Mandrioli J, McDermott C, Meyer T, Mora J, Petri S, Povedano M, Reviers E, Riva N, Roes K, Rubio M, Salachas F, Sarafov S, Sorarù G, Stević Z, Svenstrup K, MØller A, Turner M, Van Damme P, Van Leeuwen L, Varona L, VÁzquez Costa J, Weber M, Hardiman O, van den Berg L. Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotroph Lateral Scler Frontotemporal Degener 2022; 23:481-488.
Feb 16, 2022Clinical trials in pediatric ALS: a TRICALS feasibility study.
Feb 16, 2022Amyotroph Lateral Scler Frontotemporal Degener 2022; 23:481-488
Kliest Tessa, van Eijk Ruben P A, Al-Chalabi Ammar, Albanese Alberto, Andersen Peter M, Amador Maria Del Mar, BrÅthen Geir, Brunaud-Danel Veronique, Brylev Lev, Camu William, de Carvalho Mamede, Cereda Cristina, Cetin Hakan, Chaverri Delia, Chio Adriano, Corcia Philippe, Couratier Philippe, De Marchi Fabiola, Desnuelle Claude, van Es Michael A, Esteban JesÚs, Filosto Massimiliano, GarcÍa Redondo Alberto, Grosskreutz Julian, Hanemann Clemens O, Holmøy Trygve, HØyer Helle, Ingre Caroline, Koritnik Blaž, Kuzma-Kozakiewicz Magdalena, Lambert Thomas, Leigh Peter N, Lunetta Christian, Mandrioli Jessica, McDermott Christopher J, Meyer Thomas, Mora Jesus S, Petri Susanne, Povedano Monica, Reviers Evy, Riva Nilo, Roes Kit C B, Rubio Miguel Á, Salachas François, Sarafov Stayko, Sorarù Gianni, Stević Zorica, Svenstrup Kirsten, MØller Anette Torvin, Turner Martin R, Van Damme Philip, Van Leeuwen Lucie A G, Varona Luis, VÁzquez Costa Juan F, Weber Markus, Hardiman Orla, van den Berg Leonard H
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Lingor P, Koch J, Ludolph A, Frontini R, Blankenstein C, Bidner H, Kuzma-Kozakiewicz M, Benatar M, Günther R, Neuwirth C, Leha A, Hilgers R, Friede T, Camu W, Weber M, ROCK-ALS Investigators. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol 2019; 10:293.
Mar 27, 2019ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Mar 27, 2019Front Neurol 2019; 10:293
Lingor Paul, Koch Jan C, Ludolph Albert, Frontini Roberto, Blankenstein Christiane, Bidner Helen, Kuzma-Kozakiewicz Magdalena, Benatar Michael, Günther René, Neuwirth Christoph, Leha Andreas, Hilgers Reinhard, Friede Tim, Camu William, Weber Markus, ROCK-ALS Investigators
A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories
Kubisch C, de Carvalho M, Lloyd-Jani A, Konno T, DeJesus-Hernandez M, Angerbauer S, Daoud H, Just W, Tradowsky D, Mouzat K, Landers J, Veldink J, Andersen P, Rademakers R, Van Broeckhoven C, van den Berg L, Rouleau G, Shaw C, Gitler A, Silani V, Nordin A, Calini D, Birve A, Onodera O, Neitzel B, Camu W, Lumbroso S, Leblond C, Van den Broeck M, van Blitterswijk M, Volk A, van Rheenen W, Pinto S, Weber M, Alstermark H, van der Zee J, Ratti A, Chesi A, Keagle P, Talbot K, Proven M, Smith B, Akimoto C. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet 2014; 51:419-24.
Apr 4, 2014A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories
Apr 4, 2014J Med Genet 2014; 51:419-24
Kubisch Christian, de Carvalho Mamede, Lloyd-Jani Anjali, Konno Takuya, DeJesus-Hernandez Mariely, Angerbauer Sabrina, Daoud Hussein, Just Walter, Tradowsky Daniela C, Mouzat Kevin, Landers John E, Veldink Jan H, Andersen Peter M, Rademakers Rosa, Van Broeckhoven Christine, van den Berg Leonard H, Rouleau Guy A, Shaw Christopher E, Gitler Aaron D, Silani Vincenzo, Nordin Angelica, Calini Daniela, Birve Anna, Onodera Osamu, Neitzel Birgit, Camu William, Lumbroso Serge, Leblond Claire S, Van den Broeck Marleen, van Blitterswijk Marka, Volk Alexander E, van Rheenen Wouter, Pinto Susana, Weber Markus, Alstermark Helena, van der Zee Julie, Ratti Antonia, Chesi Alessandra, Keagle Pamela, Talbot Kevin, Proven Melanie, Smith Bradley, Akimoto Chizuru
Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?
Felbecker A, Camu W, Valdmanis P, Sperfeld A, Weibel S, Steinbach P, Rouleau G, Ludolph A, Andersen P. Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?. J Neurol Neurosurg Psychiatry 2010; 81:572-577.
Jun 17, 2010Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?
Jun 17, 2010J Neurol Neurosurg Psychiatry 2010; 81:572-577
Felbecker Ansgar, Camu William, Valdmanis Paul N, Sperfeld Anne-Dörte, Weibel Stefan, Steinbach Peter, Rouleau Guy A, Ludolph Albert C., Andersen Peter M